THE IMPACT OF INNOVATIVE MONOCLONAL ANTIBODY TREATMENTS ON SARS-COV2 INFECTION
CONSTANȚA-ANGELICA VIȘAN 1,2, DIANA-ELENA VIȘAN 3* , AIDA ISABELA ADAMESCU 1,2 , CĂTĂLIN TILIȘCAN 1,2, NICOLETA MIHAI 1,2, LAURENȚIU-MIHAIȚĂ STRATAN 1,2, ȘTEFAN SORIN ARAMĂ 1,2, CĂTĂLIN-MIHAI BALACI 4, ANCA STREINU-CERCEL 1,2, VICTORIA ARAMĂ 1,2, ANA-MARIA TUDOR 1,2
1 “Carol Davila” University of Medicine and Pharmacy, 37 Dionisie Lupu Street, 020021 Bucharest, Romania
2 National Institute for Infectious Diseases “Prof. Dr. Matei Bals”, 021105 Bucharest, Street Dr. Calistrat Grozovici nr.1, Romania
3 National Institute for Diabetes, Nutrition and Metabolic Diseases ”Prof. Dr. Nicolae Paulescu”, str Ion Movilă, nr.5-7, Bucharest, Romania
4 University Emergency Hospital of Bucharest, 169 Splaiul Independenței, Sector 5, Bucharest, Romania
Download Full Article PDF
The development of biopharmaceutical products has represented a true turning point in the history of modern medicine. Among them, monoclonal antibodies represent one of the most important therapeutic classes, being used both in diagnosis and research, and especially in the treatment of a wide range of conditions: autoimmune, infectious, oncological, allergic, neurological, degenerative. The COVID-19 pandemic would have had much more serious consequences without the unprecedented mobilisation of all researchers and medical workers around the world. Biological treatments represented by monoclonal antibodies have changed the dire prognosis of this disease, preventing clinical progression, as well as decreasing the number of hospitalizations and mortality rate. We conducted a retrospective study on a group of 197 patients confirmed with SARS- CoV-2 infection, in which we evaluated the impact of administering the combination of monoclonal antibodies Casirivimab - Imdevimab on clinical progression and the need for hospitalisation. The way in which monoclonal antibody treatment has radically altered the course of COVID-19 in patients highlights the essential role of innovative treatment modalities in shaping the trajectory of severe diseases.
